Press Release

ZEISS Vision Care invests into CREAL

Move reinforces the company’s commitment to remain at the forefront of technological advancements in the eyecare industry

10 September 2024

Lausanne, Switzerland / Aalen, Germany | 10 September 2024 | ZEISS Vision Care

ZEISS Vision Care announces on September 10th the successful completion of a minority investment into CREAL, a company offering innovative light field display technology. This strategic move solidifies ZEISS' commitment to advancing technology in the eyecare industry and further opens new opportunities for the development of innovative optometric workflow solutions for consumers and EyeCare Professionals.


Leveraging CREAL’s light field display technology, ZEISS expects to create a digitized vision care platform intended to revolutionize the eyewear customer buying experience. The company will work on solutions allowing for the digital examination and diagnosis of eye conditions.
 

 

Current refraction method vs. CREAL light-field digital solution

“As the pioneer of scientific optics, ZEISS’ mission has always been to challenge the limits of human imagination,” says Antia Alonso Ph.D., Vice President of Zeiss Vision Technology Solutions. "We see our collaboration with CREAL and the consequent development and rollout of our digitized vision care platform as a way to revolutionize the prescription eyewear customer buying experience, elements of which still rely on technology developed over a century ago."

CREAL’s light field display technology replicates real world light, delivering digital imagery with natural focus depth, and uniquely enabling purely digital visualisation of optical refraction. This allows for precise digital diagnosis of eye defects, for prescription lens simulations, as well as for software vision correction in virtual environments.
 

Portrait Joachim Kuss
Press contact Joachim Kuss General Topics and Sustainability

ZEISS Vision Care

About CREAL

CREAL is a display technology startup based in Switzerland, with a technical team drawn from cutting-edge projects at Intel, Magic Leap, EPFL and CERN. CREAL has developed a patented light field micro-display technology stack, uniquely projecting images with true-to-life depth. While serving vision care applications, CREAL naturally expands its mission toward Augmented Reality hardware. With the same business model and partners among the market leaders in the vision care/eyewear industry, CREAL ultimately enables a much-needed natural and healthy visual experience of digital content. To know more, please visit www.creal.com.

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).

For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With more than 44,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, 35 research and development facilities, and 35 production facilities worldwide (status: 31 March 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

 

ZEISS Vision Care
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand.


Share this article


  • 1

    ”The Consumer inSights Q1 2002 report”, The Vision Council’s

     

  • 2

    Padmaja Sankaridurg, et al, ”Impact of Myopia,” ARVO Journals, Investigative Ophthalmology & Visual Science, Vol.62, 2, April 2021